Trading on a major exchange can give a company access to a significant pool of investors, meaning easier access to funding and expedited growth. That's why listing on an exchange like the NYSE or NASDAQ is the goal for many pot stocks. However, with marijuana still illegal at th
Besides working on a vaccine for the coronavirus, British American Tobacco (NYSE: BTI) is one of the top three tobacco companies in the world, alongside Altria Group and Philip Morris International.
There are quite a few companies that have found ways to grow their business during the ongoing COVID-19 pandemic. This is especially true for a number of biotechs now working on developing a potential treatment for, or vaccine against, the virus; shares of such companies have la
Small-cap vaccine manufacturers have been some of the most volatile stocks on the market. As demand for a COVID-19 vaccine continues to grow, many companies working on potential treatments have seen their shares double or triple since the start of 2020.
Spirit AeroSystems (NYSE: SPR) has halted work on Boeing (NYSE: BA) commercial aircraft fuselages and furloughed more than 3,000 workers for 21 days following Boeing's decision to suspend final assembly due to the COVID-19 coronavirus pandemic.
Believe it or not, there will come a time when the coronavirus contagion is in the rearview mirror. For a few people, life will have changed dramatically. For most people, life will have changed at least a little. Whether it be due to a job loss, concern about the cleanliness of
Cannabis sales were soaring in March, especially during the first half of the month as the coronavirus became a global pandemic. Washington state saw a 9% increase in March's revenue from cannabis compared to the prior year, California's sales were up 53% year over year (althoug
When a company develops products that should be game changers in the way cancer is treated, it's going to generate a lot of buzz. That's exactly what has happened for Guardant Health (NASDAQ: GH).
In most years, April isn't a special month to buy stocks. It's not a bad time to invest, but there's nothing that makes April better than other months. But this April is different.
In most years, April isn't a special month to buy stocks. It's not a bad time to invest, but there's nothing that makes April better than other months. But this April is different.
Inovio Pharmaceuticals (NASDAQ: INO) has been making a lot of headlines lately. Thanks to its efforts to develop a vaccine for COVID-19, the company's stock is up by 150% year to date.
Marijuana users in Oregon bought $84.5 million worth of licensed product in March, according to data compiled by the state's Liquor Control Commission and cited in various media. That tally was 6.4% higher than in the previous month, and 30% above the March 2019 result. March 20
BioCryst Pharmaceuticals (NASDAQ: BCRX) has started a clinical trial to test its antiviral medication galidesivir in patients with COVID-19. The U.S. government's National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, is fundin
The following are today's upgrades for Validea's Contrarian Investor model based on the published strategy of David Dreman. This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.
The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.
The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
The following are today's upgrades for Validea's Book/Market Investor model based on the published strategy of Joseph Piotroski. This value-quant strategy screens for high book-to-market stocks, and then separates out financially sound firms by looking at a host of improving f